Results are in for a new depression drug trial, and they're cratering this stock
Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Contract Pharma4d
Neumora’s KOSTAL-1 Study of Navacaprant Yields Disappointing Results
The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...
FierceBiotech6d
Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%
The biotech reported data from KOASTAL-1, the first of three phase 3 trials of navacaprant in major depressive disorder.
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals
Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...
Monthly Prescribing Reference5d
Navacaprant Falls Short in Major Depressive Disorder Trial
Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...
Neumora Shares Plunge As Navacaprant Misses Key Endpoints In Major Depressive Disorder Trial
Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of ...
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...
BioPharma Dive5d
Neumora plummets on depression drug data
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...
Business Insider6d
Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression
Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate Phase ...
Neumora Stock Dives After Study Failure
Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with ...